BMI and ASCAP are both composers, songwriters, lyricists, and music publishers of every kind of music. To join BMI there is an application fee of $150, however the publisher fee is $250. BMI is associated with famous music artist such as, Legendary Toni Braxton, Kirk Franklin, Rihanna, Nicki Minaj, and Bryson Tiller. BMI offers Royalties and they include Radio, TV, and the internet. On the other hand over at ASCAP they a $50 writers processing fee and a $50 publisher processing fee. Their Royalties include TV, performances, and the radio. ASCAP is associated with talented people such as, The Weekend, Justin Bieber, Fetty Wap, and Adele. Both BMI and ASCAP are well known and work with famous, popular and talented people and offer reasonable,
Opioid addiction is so prevalent in the healthcare system because of the countless number of hospital patients being treated for chronic pain. While opioid analgesics have beneficial painkilling properties, they also yield detrimental dependence and addiction. There is a legitimate need for the health care system to provide powerful medications because prolonged pain limits activities of daily living, work productivity, quality of life, etc. (Taylor, 2015). Patients need to receive appropriate pain treatment, however, opioids need to be prescribed after careful consideration of the benefits and risks.
As previously discussed, the program the author would choose to evaluate is MAT treatment programs. This population consists of individuals that have been diagnosed with opiate use disorder, and receive opiate-substitution medications, such as Methadone or Suboxone. These program evaluations would be consumer-centered, performed in the clinics they receive services. Interested stakeholders would include the treatment center where the participants receive services, as well as other MAT service providers. Additionally, the funding sources for these individuals and program centers, such as county, state, and federal agencies, along with medical insurers, would also gain value from the program evaluation research.
The guideline named opioid cumulative dosing override allows for an override for an opioid product equal to or exceeding the hard-stop threshold (60mg morphine equivalent dose) and a 7 day supply. An override will be provided for patients with one of the following conditions: diagnosis of cancer, palliative care, or sickle cell disease, patients enrolled in hospice care, or patients taking an opiate tapering regimen following an orthopedic procedure with an end date not to exceed 21 days. For all other patients, the prescriber must be aware that all of the following criteria must be met: the diagnosis for use of the opiate and reason for continued use are documented, previous trials of non-drug and/or non-opiate use are documented, the patient does not have concurrent use of benzodiazepines
ESSENCE OF THE STORY: In the past few years, opioid addiction has become an epidemic in the United States leading to around 64,000 people dying from drug overdose in 2016 alone. As a result the health and human services secretary, Mr. Azar, and the F.D.A. chief, Dr. Scott Gottlieb, has made battling opioid addiction a top priority. The main way the F.D.A. is attempting to battle the epidemic is by allowing pharmaceutical companies to sell new types of medications that aren’t meant to stop addiction but to help suppress the cravings of addiction. The new medication that the F.D.A is approving is supposed to be a part of the program MAT, or medication-assisted-treatment. Mr. Azar as well as Dr. Scott have been pushing for more MAT in hope to help people with addiction live productive lives. Though like most big changes in society, the F.D.A’s decision has drawn criticism. Addiction experts are saying that new medication isn’t the solution but more access to the medication is.
Pharmacy has been consulted regarding: How do the outcomes compare between buprenorphine-containing treatment options and methadone in opioid-dependent patients in terms of efficacy?
George E. Woody, M.D. of the Treatment Research Institute at the University of Pennsylvania who conducted the study with his colleagues stated, “It’s hard to say what the ideal length of time for treatment is. When you start treatment, there are psychological features of addiction. First, you want to make sure they are not taking anything other than the methadone or the Suboxone. Then they need to be in a stable psychosocial situation. You want them to feel ready for it. And then, and only then, do you do the taper. But you still have to follow them, and not be hesitant to restart them. Because if they don’t do well, they can overdose and die” (Drug and Alcohol Weekly, 2008).
The main threats identified in the study fall under the historical category. The study began with 175 participants beginning treatment, but only 131 women finished the study; 28 women on buprenorphine and 16 women on methadone dropped out of the study, showing distinctly different rates of attrition. As a result, the outcomes of the study could have shown bias in favor of the buprenorphine group. However, statistically, there were no significant between-group differences in women who completed the study and those who did not, suggesting that the differences in attrition rates are unlikely to explain the outcomes. The authors of the study explicitly addressed this concern and stated that the results should, “Be considered in light of the markedly different rates of attrition” (Jones, et al, 2010, p. 2330). They also discussed possible reasons for the differences in attrition rates and said that the rates should not matter as the final analysis conducted excluded women who were on over 100 mg of methadone, removing 19% of the sample. In terms of subject maturation, testing, and instrumentation, there are no
One thing contributing to the high usage of opiates is their ability to have strong pain relieving effects. The availability of prescription medications containing opium contributed to the misuse and abuse of the substance as well (Chen, Humphreys, & Shah, 2013, p. 60). Since opiates were easy to possess from medical personnel, it became clear that it was contributing to issues related to the misuse and abuse of opiates (Chen, Humphreys, & Shah, 2013, p. 60). Therefore, over the past few years, prescription drugs which possessed addictive qualities such as opioids, has been closely monitored to avoid nonmedical usage (Chen, Humphreys, & Shah, 2013, p. 60). Nonmedical prescription drug use and disorders are pervasive in the U.S. population, it also tends to be highly comorbid with other psychiatric disorders (Huang, et al., 2006, p.
Objectives/Progress: Pt. developed and shared personal plans to avoid triggers, to break the cycle of procrastination and stay on his successful path of recovery. Pt. has made excellent progress on maintaining his commitment to abstinence as indicated by his clean UDS results since his admission and always attending scheduled AMS therapy groups. Pt. indicated that he is responding as expected to his prescribed 8 mg of subutex medication.
“Americans account for 99% of the worlds hydrocodone consumption, 80% of the worlds oxycodone consumption and 65% of the worlds hydromorphone consumption, according to the New York Times” (Elkins, 2015). Pain killers are one of the most abused drugs in the United States. “Every year, prescription pain killers cause more than 16,000 deaths and 475,000 emergency room visits” (Elkins, 2015). The proposed bill HB 330(BR-990) will be beneficial to the healthcare industry. One step that has been made to deter drug abuse is the development of opioids that are formulated to deter abuse. “An abuse-deterrent formulations
Many studies involving XR-NTX treatment require participants to remain abstinent prior to treatment or they are excluded from participation. In terms of improving outpatient treatment with XR-NTX, Mannelli, et al. (2014) attempted to address the issue of patients being able to maintain an abstinent state prior to receiving XR-NTX. The results of the pilot study suggest that gradually increasing low doses of naltrexone while gradually decreasing low doses of Suboxone can successfully transition patients to XR-NTX administration. Because this was a pilot study, it is recommended thata double-blind, placebo-controlled study be conducted with a larger sample size. The importance of being able to mitigate the difficulty some patients may face obtaining a prolong abstinent-state is crucial if XR-NTX is to take a leading role in OUD pharmacotherapy. These finding could be particularly important for patients that have limited or no access to
Determinants of mortality related to opioids among Canada and the United States were studied by King and Associates (2014). The purpose of this study was to examine 17 factors that impact the mortality that is opioid-related. Several electronic databases were used to
Inpatients in adult psychiatric units who are diagnosed with chronic pain may be perceived as narcotic abusers. Even with the complete, proper physical and history assessment, it may not be fully determined whether or not they are receiving the sufficient pain regimen. The subjects who take part in this research are patients in a hospital’s psychiatric unit and must be diagnosed with chronic pain in order to fit the category. Healthcare providers classify psychiatric patients to abuse the healthcare system for the intention of obtaining free narcotics. The issue of this insight is
however, these effects are weaker than those of full drugs such as heroin and methadone”